These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 14687852

  • 1. Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.
    Pajonk FG.
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):15-23. PubMed ID: 14687852
    [Abstract] [Full Text] [Related]

  • 2. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ, Ayuso JL, Gutiérrez M, Guimon J, Herraiz ML, Chinchilla A, Ayuso JL, González Pinto A, Eguiluz I, Fernández A.
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996 Jan; 24(4):165-72. PubMed ID: 8984849
    [Abstract] [Full Text] [Related]

  • 3. Long-acting injectable risperidone.
    Ehret MJ, Fuller MA.
    Ann Pharmacother; 2004 Dec; 38(12):2122-7. PubMed ID: 15522979
    [Abstract] [Full Text] [Related]

  • 4. Risperidone: an analysis of the first three years in general use.
    Gutierrez-Esteinou R, Grebb JA.
    Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 4():S3-10. PubMed ID: 9352340
    [Abstract] [Full Text] [Related]

  • 5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 6. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM, Nepal MK, Koirala NR, Sharma VD, Gurung CK, Adhikari SR.
    Kathmandu Univ Med J (KUMJ); 2006 Dec; 4(2):152-60. PubMed ID: 18603890
    [Abstract] [Full Text] [Related]

  • 7. Acute phase of schizophrenia: impact of atypical antipsychotics.
    Azorin JM.
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S5-9. PubMed ID: 11252521
    [Abstract] [Full Text] [Related]

  • 8. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J.
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
    Ruhrmann S, Kissling W, Lesch OM, Schmauss M, Seemann U, Philipp M.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun 30; 31(5):1012-22. PubMed ID: 17412473
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M.
    J Clin Psychiatry; 2004 Aug 30; 65(8):1084-9. PubMed ID: 15323593
    [Abstract] [Full Text] [Related]

  • 11. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
    Philipp M, Lesch OM, Schmauss M, Dose M, Glaser T.
    Psychiatr Prax; 2003 May 30; 30 Suppl 2():S94-6. PubMed ID: 14509050
    [Abstract] [Full Text] [Related]

  • 12. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
    Kane JM.
    J Clin Psychiatry; 2003 May 30; 64 Suppl 19():19-25. PubMed ID: 14728086
    [Abstract] [Full Text] [Related]

  • 13. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA, Morrens M, Sabbe BG.
    Clin Ther; 2008 Sep 30; 30(9):1565-89. PubMed ID: 18840365
    [Abstract] [Full Text] [Related]

  • 14. Long-acting risperidone: focus on safety.
    Möller HJ.
    Clin Ther; 2006 May 30; 28(5):633-51. PubMed ID: 16861087
    [Abstract] [Full Text] [Related]

  • 15. The Canadian experience with risperidone for the treatment of schizophrenia: an overview.
    Iskedjian M, Hux M, Remington GJ.
    J Psychiatry Neurosci; 1998 Sep 30; 23(4):229-39. PubMed ID: 9785702
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M, Kuwilsky A, Krumm B, Dressing H.
    J Psychopharmacol; 2009 May 30; 23(3):305-14. PubMed ID: 18562423
    [Abstract] [Full Text] [Related]

  • 17. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.
    Carter CS, Mulsant BH, Sweet RA, Maxwell RA, Coley K, Ganguli R, Branch R.
    Psychopharmacol Bull; 1995 May 30; 31(4):719-25. PubMed ID: 8851645
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
    Möller HJ, Pelzer E, Kissling W, Riehl T, Wernicke T.
    Pharmacopsychiatry; 1991 Nov 30; 24(6):185-9. PubMed ID: 1725925
    [Abstract] [Full Text] [Related]

  • 19. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
    Rémillard S, Pourcher E, Cohen H.
    J Int Neuropsychol Soc; 2008 Jan 30; 14(1):110-8. PubMed ID: 18078537
    [Abstract] [Full Text] [Related]

  • 20. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
    Faludi G.
    Neuropsychopharmacol Hung; 2005 Mar 30; 7(1):22-7. PubMed ID: 16167464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.